Asset Details
Do you wish to reserve the book?
New Classes of Alanine Racemase Inhibitors Identified by High-Throughput Screening Show Antimicrobial Activity against Mycobacterium tuberculosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
New Classes of Alanine Racemase Inhibitors Identified by High-Throughput Screening Show Antimicrobial Activity against Mycobacterium tuberculosis
Do you wish to request the book?
New Classes of Alanine Racemase Inhibitors Identified by High-Throughput Screening Show Antimicrobial Activity against Mycobacterium tuberculosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
New Classes of Alanine Racemase Inhibitors Identified by High-Throughput Screening Show Antimicrobial Activity against Mycobacterium tuberculosis
2011
Overview
In an effort to discover new drugs to treat tuberculosis (TB) we chose alanine racemase as the target of our drug discovery efforts. In Mycobacterium tuberculosis, the causative agent of TB, alanine racemase plays an essential role in cell wall synthesis as it racemizes L-alanine into D-alanine, a key building block in the biosynthesis of peptidoglycan. Good antimicrobial effects have been achieved by inhibition of this enzyme with suicide substrates, but the clinical utility of this class of inhibitors is limited due to their lack of target specificity and toxicity. Therefore, inhibitors that are not substrate analogs and that act through different mechanisms of enzyme inhibition are necessary for therapeutic development for this drug target.
To obtain non-substrate alanine racemase inhibitors, we developed a high-throughput screening platform and screened 53,000 small molecule compounds for enzyme-specific inhibitors. We examined the 'hits' for structural novelty, antimicrobial activity against M. tuberculosis, general cellular cytotoxicity, and mechanism of enzyme inhibition. We identified seventeen novel non-substrate alanine racemase inhibitors that are structurally different than any currently known enzyme inhibitors. Seven of these are active against M. tuberculosis and minimally cytotoxic against mammalian cells.
This study highlights the feasibility of obtaining novel alanine racemase inhibitor lead compounds by high-throughput screening for development of new anti-TB agents.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Alanine Dehydrogenase - metabolism
/ Alanine Racemase - antagonists & inhibitors
/ Alanine Racemase - chemistry
/ Alanine Racemase - metabolism
/ Alanine Racemase - pharmacology
/ Analogs
/ Anti-Infective Agents - analysis
/ Anti-Infective Agents - chemistry
/ Anti-Infective Agents - classification
/ Anti-Infective Agents - pharmacology
/ Antiinfectives and antibacterials
/ Biology
/ Drugs
/ Enzyme Inhibitors - analysis
/ Enzyme Inhibitors - chemistry
/ Enzyme Inhibitors - classification
/ Enzyme Inhibitors - pharmacology
/ Enzymes
/ High-Throughput Screening Assays - methods
/ Humans
/ Kinetics
/ Medicine
/ Mycobacterium tuberculosis - drug effects
/ Substrate Specificity - drug effects
/ Suicide
/ Toxicity
